Our most recent research was able to identify differences in the breath measurements of women with early-stage breast cancer compared to those without breast cancer with 88.2% accuracy. A sub-group analysis found that breast tissue density had no noticeable effect on the results. This groundbreaking research was conducted by Dr. Farah Naz, using Breathe BioMedical’s technology, and was published as an online abstract at the ASCO 2023 Annual Meeting.
ISO 13485 Certified is an international standard for quality systems for medical device manufacturers across the globe. This certification demonstrates, by third party review, that Breathe BioMedical’s full end-to-end quality management system meets the highest standard for safety and quality.